Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.
Impact of Philips' decision to halt CPAP device sales in the U.S. and its potential market implications. William Blair sees a significant opportunity for Inogen to reclaim market share.
Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.
Bridgewater Associates, founded by Ray Dalio, made notable changes to its portfolio in Q4 2023. New bets, exits, increased stakes offer insights into its investment strategy.
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients.
Recursion Pharmaceuticals' approach to drug discovery. NVIDIA's $75.9 million stake amplifies the impact of generative AI in identifying innovative treatments.